Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement ...

Shares of Incyte Corp. INCY slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...

In a report released on April 17, Jessica Fye from J.P. Morgan maintained a Hold rating on Halozyme (HALO – Research Report), with a price ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

It was testing an oral therapy for a skin disorder. On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe ...